EP300 and prostate carcinoma: The level of JMJD1A acetylation was increased in drug-resistant prostate cancer cell lines, and subsequent experiments also demonstrated that p300 inhibitors significantly inhibited the proliferation of resistant prostate cancer cell lines and increased the sensitivity of these tumour cells to AR antagonists [4].